About avelumab
PD-L1 immune checkpoint inhibitor
Used for
- Treats Merkel cell carcinoma.
- Treats advanced renal cell carcinoma with axitinib.
- Treats certain advanced urothelial cancers.
Usual adult dose
800 mg intravenously every 2 weeks, or 1,200 mg every 3 weeks, depending on indication and regimen.
Common side effects
- Tiredness
- Infusion reactions
- Diarrhea
- Immune-related inflammation of organs
Important warnings
- Can cause serious immune reactions affecting organs, including lungs, liver, bowel, and hormone glands.
- Infusion reactions can be severe or life-threatening.
- Monitor for immune-related side effects during treatment and after stopping.
- Treatment requires specialist supervision.
Pregnancy
May harm an unborn baby; pregnancy should be avoided during treatment and for at least 1 month afterward.
Breastfeeding
Do not breastfeed during treatment and for at least 1 month after the last dose.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.